Corvus Pharmaceuticals, Inc.
CRVS
$13.99
-$0.09-0.64%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -12.32M | -10.16M | -8.00M | 15.19M | -12.11M |
| Total Depreciation and Amortization | 26.00K | 28.00K | 29.00K | 22.00K | 20.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.02M | 1.11M | -701.00K | -23.63M | 5.09M |
| Change in Net Operating Assets | 1.08M | -550.00K | 2.89M | 152.00K | -1.46M |
| Cash from Operations | -9.19M | -9.57M | -5.78M | -8.26M | -8.47M |
| Capital Expenditure | -25.00K | 0.00 | -113.00K | -36.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | 5.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 10.91M | -2.62M | -20.19M | 4.28M | -6.09M |
| Cash from Investing | 10.88M | -2.62M | -20.30M | 4.24M | -6.08M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 20.00K | 360.00K | 35.77M | 279.00K | 18.61M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 0.00 |
| Cash from Financing | 20.00K | 360.00K | 35.77M | 279.00K | 18.61M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.71M | -11.82M | 9.69M | -3.74M | 4.06M |